

7th May 2024

Contact:

silvia.humera@accessvetmed.eu

Tel. + 34 606848551

12 years of continuous growth for the main players in the veterinary generic and added-value medicines industry in Europe.

Access VetMed members declare a turnover above €2,4 billion in 2023

- With a 10% growth compared to 4% in 2022, this industry remains on a consistent upward trend.
- The average sales per company also increased, from €86 million in 2022 to €91 million in 2023.

Brussels, 7th May 2024- Access VetMed, the voice of the European industry of generic and added-value veterinary medicines, has just published its yearly [Annual Report for 2023](#), highlighting once more the growth trend of the European generic and added-value medicines business.

The data, collected from its **27 members** through a survey, also confirms continuous growth in employees and sales of these companies to non-European Union countries, which have been 4% above those from the last exercise.

Access VetMed membership generated over **€2.4 billion (10% higher than in 2022)** and supported more than **8.600 direct jobs in the EU** (8.200 last year), holding **45% of all generic veterinary medicines marketing authorizations in Europe**. The average sales per company also increased, from €86 million in 2022 to €91 million in 2023.

According to Access VetMed chair, **Xavier Molins**, the data highlights the strength and also the potential of our industry in Europe. “When I initially joined Access VetMed, approximately 15 years ago, we were a relatively small consortium of companies representing the animal health generic industry in Europe. However, with the commitment of those founding companies and the excellent leadership of the Board at Access VetMed, our Association has experienced significant growth as the figures reflect. Most importantly, during these years, Access VetMed has successfully established itself as a recognized stakeholder within the relevant EU Competent Authorities, giving us a sense of being listened to”.

As possible threats, the association points out the complicated geopolitical situation and the difficulties faced by its members, sometimes small companies, in coping with the requirements and bureaucracy demanded by the legislative changes in the EU. “The economic impact of compliance issues have been reflected in many cases in the reduction of the veterinary medicines industry portfolios, especially in those smaller companies”, said **Xavier Molins**.

For 2024, Access VetMed efforts are mainly focused on ensuring any outstanding implementing and delegated acts from UE Regulation 2019/6 are aligned with its mission: to increase ACCESS – availability, compliance, convenience, efficacy, safety, and savings – of veterinary medicines to veterinarians, farm, and companion animal owners in Europe.

Figure I: Access VetMed members performance in 2023

Year	Members	Global sales veterinary medicines		EU sales veterinary medicines		Sales distribution		Employees (veterinary business)	
		Total Turnover	Average company	Total Turnover	Average company	EU	Non-EU	Total Number	Average company
2011	21	936.323.743,00 €	44,5 Mi €	NA	-	-	-	3.423	163
2013	22	1.218.955.009,00 €	55,5 Mi €	NA	-	-	-	4.476	203
2015	21	1.297.969.537,00 €	62 Mi €	NA	-	-	-	5.031	240
2017	22	1.414.722.199,00 €	64,3 Mi €	NA	-	-	-	5.814	264
2018	24	1.585.111.715,00 €	66 Mi €	946.396.397,00 €	39,4Mi €	60%	40%	6.159	257
2019	26	1.802.882.700,00 €	69,3 Mi €	1.122.476.113,00 €	43,2Mi €	62%	38%	7.246	279
2020	26	1.926.560.780,57 €	74,1 Mi €	1.217.901.761,43 €	46,8 Mi €	63%	37%	7.574	291
2021	26	2.151.507.911,68 €	82,7 Mi €	1.382.255.950,43 €	53,2 Mi€	64%	36%	7.933	305
2022	26	2.235.619.550,53 €	86 Mi €	1.456.743.242,96 €	56,8 Mi€	65%	35%	8.174	312
2023	27	2.459.595.656,54 €	91 M i€	1.496.892.792,59 €	56,8 Mi€	61%	39%	8.635	324

*NA (Not Available)

About Access VetMed

Access VetMed was founded in 2002 as the European Group for Generic Veterinary Products (EGGVP) to serve as the voice of the generic veterinary medicines industry in Europe. Today, we represent **27 generic and added-value veterinary medicines companies** located in various European countries, including smaller markets. Together, our members have **a turnover of over 2,4 billion euros** and support **more than 8.600 direct jobs, holding 45% of all generic veterinary medicines marketing authorizations** in Europe.

We actively and constructively engage with EU regulators and other stakeholders to advocate for transparent, harmonized, pragmatic and balanced animal health regulation. Our primary objective is to increase ACCESS – availability, compliance, convenience, efficacy, safety, and savings – of veterinary medicines to veterinarians, farm, and companion animal owners in Europe.

More information: www.accessvetmed.eu

###